-
公开(公告)号：US20200164091A1
公开(公告)日：2020-05-28
申请号：US16739245
申请日：2020-01-10
申请人： Canji, Inc.
发明人： William F. BENEDICT
摘要： The present invention provides a method for the treatment of lung cancer through the use of a recombinant gene therapy vector having a transgene encoding interferon. In particular it is noted that interferon when expressed by a recombinant gene therapy vectors possesses properties not associated with exogenously-manufactured interferon proteins. The present disclosure thus provides a method useful in the treatment of lung tumors such as mesothelioma, using a recombinant gene therapy vector having a transgene encoding interferon.
-
2.发明申请COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAV1.8 有权短期干扰NAV1.8的核酸抑制剂的组合物和方法公开(公告)号：US20100305192A1
公开(公告)日：2010-12-02
申请号：US12789564
申请日：2010-05-28
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短链干扰核酸，单链或双链，其导致RNAi诱导的来自Nav1.8钠通道基因的mRNA降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
公开(公告)号：US07691370B2
公开(公告)日：2010-04-06
申请号：US10062216
申请日：2002-01-30
CPC分类号： C12N15/86 , A61K48/00 , C12N2710/10332 , C12N2710/10343 , C12N2830/00 , C12N2830/001 , C12N2830/15
摘要： The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.
摘要翻译： 本发明提供了通过使用基于感染细胞的表型或基因型基本上抑制宿主细胞中的病毒复制的途径反应性启动子来响应于靶细胞的细胞内条件而选择性复制病毒基因的重组病毒。 在靶细胞中，途径反应性启动子的启动子元件是无活性的，因此病毒被允许复制。 这导致：（1）通过病毒的天然裂解性质杀死细胞，和/或（2）向靶细胞提供治疗剂量的转基因产物（与复制无能载体相比扩增），和（3） 产生该病毒的局部浓度，促进周围细胞感染重组病毒。 本发明还提供了使用载体的治疗和诊断方法，包含载体的药物制剂，制备载体的方法和包含载体的转化细胞。
-
公开(公告)号：US07538093B2
公开(公告)日：2009-05-26
申请号：US11359997
申请日：2006-02-21
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译： 一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X1是胆酸基或脱氧胆酸基; X2和X3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中所述糖基选自戊糖单糖基，己糖单糖基，戊糖 - 戊糖基 二糖基团，己糖 - 己糖二糖基团，戊糖 - 己糖二糖基团和己糖 - 六糖二糖基团; 并且其中X 2和X 3中的至少一个是糖基团。
-
公开(公告)号：US07534769B2
公开(公告)日：2009-05-19
申请号：US10055863
申请日：2002-01-22
CPC分类号： A61K31/56 , A61K31/7008 , A61K48/00 , C07J9/005 , C07J41/0061 , C12N15/87
摘要： This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
-
公开(公告)号：US20090082289A1
公开(公告)日：2009-03-26
申请号：US11800036
申请日：2007-05-02
CPC分类号： C12N15/86 , A61K48/00 , C12N2710/10332 , C12N2710/10343 , C12N2830/008 , C12N2830/85
摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.Thus, for example, the adenoviral vector of this invention- can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
摘要翻译： 本发明提供一种重组腺病毒表达载体，其特征在于部分或完全缺失腺病毒蛋白IX DNA并具有编码外来蛋白或其功能片段或突变体的基因。 转化的宿主细胞和生产重组蛋白和基因治疗的方法也包括在本发明的范围内。 因此，例如，本发明的腺病毒载体可以含有外源基因，用于表达有效调节细胞周期的蛋白质，例如p53，Rb或mitosin，或诱导细胞死亡，例如有条件的自杀 基因胸苷激酶。 （后者必须与胸苷激酶代谢物结合使用才能有效）。
-
公开(公告)号：US20080107629A1
公开(公告)日：2008-05-08
申请号：US11904993
申请日：2007-09-28
申请人： Drake LaFace , Van Tsai
发明人： Drake LaFace , Van Tsai
IPC分类号： A61K35/76
CPC分类号： C12N15/86 , A61K35/761 , A61K47/60 , A61K47/6901 , A61K48/0041 , C12N7/00 , C12N2710/10332 , C12N2710/10343 , C12N2710/10363
摘要： The present invention relates to improved methods for gene therapy, particularly gene therapy using PEGylated adenovirus. In particular the invention provides methods and compositions for mitigating the adverse effects associated with systemic administration of recombinant adenovirus for gene therapy.
摘要翻译： 本发明涉及用于基因治疗的改进方法，特别是使用聚乙二醇化腺病毒的基因疗法。 特别地，本发明提供了用于减轻与用于基因治疗的重组腺病毒的全身施用相关的不良反应的方法和组合物。
-
公开(公告)号：US20070253932A1
公开(公告)日：2007-11-01
申请号：US11684548
申请日：2007-03-09
申请人： Richard Gregory , Ken Wills , Daniel Maneval
发明人： Richard Gregory , Ken Wills , Daniel Maneval
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K35/761 , A61K38/00 , A61K38/45 , A61K48/00 , C07K14/005 , C07K14/4746 , C12N7/00 , C12N2710/10321 , C12N2710/10332 , C12N2710/10343 , C12N2830/008 , C12N2830/85 , A61K2300/00
摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
摘要翻译： 本发明提供一种重组腺病毒表达载体，其特征在于部分或完全缺失腺病毒蛋白IX DNA并具有编码外来蛋白或其功能片段或突变体的基因。 转化的宿主细胞和生产重组蛋白和基因治疗的方法也包括在本发明的范围内。 因此，例如，本发明的腺病毒载体可以含有外源基因，用于表达有效调节细胞周期的蛋白质，如p53，Rb或mitosin，或诱导细胞死亡，如条件性自杀基因 胸苷激酶。 （后者必须与胸苷激酶代谢物结合使用才能有效）。
-
9.发明申请Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene 审中-公开使用肿瘤抑制基因选择性转导病理性哺乳动物细胞的方法公开(公告)号：US20070237753A1
公开(公告)日：2007-10-11
申请号：US11706563
申请日：2007-02-14
申请人： H. Shepard , Nancy Kan
发明人： H. Shepard , Nancy Kan
IPC分类号： A61K48/00 , C12N15/867
CPC分类号： C07K14/4746 , A61K38/1709 , A61K48/00 , C07K14/47 , C12N2740/13043
摘要： A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology in a subject caused by the absence of, or the presence of a pathologically mutated tumor suppressor gene.
摘要翻译： 用于转导病理过度增殖的哺乳动物细胞的方法由本发明提供。 该方法需要使细胞与含有编码具有肿瘤抑制功能的基因产物的核酸的合适的逆转录病毒载体接触。 本发明还提供了一种用于治疗由于不存在或存在病理突变的肿瘤抑制基因导致的受试者病理学的方法。
-
公开(公告)号：US07094583B2
公开(公告)日：2006-08-22
申请号：US10913567
申请日：2004-08-06
IPC分类号： A61K48/00 , C12N15/866
CPC分类号： C12N15/87 , A61K31/715 , A61K31/724 , A61K35/761 , A61K38/1758 , A61K48/00 , A61K48/0008 , C12N15/86 , C12N2710/10332 , C12N2710/10343 , Y10S435/932 , A61K2300/00
摘要： The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.03 秒)
